Major depressive disorder (MDD) Obsessive-compulsive disorder (OCD) Panic disorder (PD) Posttraumatic stress disorder (PTSD) Social anxiety disorder (SAD) Premenstrual dysphoric disorder (PMDD)
Selective Serotonin Re-uptake Inhibitor; Antidepressant
Sertraline has potent and selective inhibitory action on CNS neuronal reuptake of 5-HT resulting in increased 5-HT concentrations at the synaptic clefts, leading to facilitation of its sustained activity at the postsynaptic receptor sites. It ultimately results in an improvement of depression. Reduction of Serotonin turnover in brain by Sertraline is also another contributing fact implicated in its action. Its prolonged elimination half-life offers a benefit of once daily administration.
ORAL Depression;Obsessive compulsive disorder: Adult: Initially, 50 mg once daily, may increase in steps of 50 mg at wkly intervals. Max: 200 mg daily. Child: For obsessive-compulsive disorder: 6-12 yr: Initially, 25 mg once daily; 13-17 yr: Initially, 50 mg once daily. May increase dose at intervals of at least 1 wk, to a max of 200 mg/day. If somnolence is noted, give at bedtime. Panic disorder w/ or w/o agoraphobia; Posttraumatlc stress disorder;Soclal anxiety disorder: Adult: Initially, 25 mg daily, increased after 1 wk to 50 mg daily. May increase in steps of 50 mg at wkly intervals. Max: 200 mg daily. Premenstrual dysphoric disorder: Adult: Initially, 50 mg daily. May be given throughout the menstrual cycle or only during the luteal phase. May increase by 50 mg each cycle if needed. Max: 150 mg daily for continuous dosing or 100 mg daily for luteal phase-only dosing. Patients who require 100 mg daily for Iuteal phase-only dosing should always start w/ 50 mg daily for the 1st 3 days of each luteal phase dosing period.
Potential effects of co-administration of drugs that are highly bound to plasma proteins- As Sertraline is tightly bound to plasma protein, the administration of Sertraline to a patient taking another drug which is tightly bound to protein, (e.g. warfarin, digitoxin) may cause a shift in plasma concentrations potentially resulting in an adverse effect. Conversely adverse effects may result from displacement of protein bound Sertraline by other tightly bound drugs. Sertraline may interact with other drugs such as Cimetidine, CNS active drugs like Diazepam, Hypoglycemic drugs, Atenolol etc.
Children <18 yr. Poorly controlled epilepsy. History of hypomania & seizure disorders, hepatic & renal impairment, cardiac disease, recent Ml, history of bleeding disorders, DM & angle-closure glaucoma. Discontinue treatment if seizures develop or if there is an increase in seizure frequency. Withdrawal should be gradual. Monitor for signs of clinical worsening, suicidality & unusual changes in behaviour esp during the initial treatment period or when there are dosage adjustments. Pregnancy & lactation.
Nausea, anorexia, dyspepsia, constipation, diarrhoea, dry mouth, flatulence, vomiting, ejaculation failure, increased sweating, somnolence, agitation, insomnia, headache, dizziness, fatigue, anxiety, nervousness, tremor, paraesthesia, decreased libido, rash, hot flushes, blurred vision.
This drug should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus, taking into account the risks of untreated depression. Use is not recommended for breastfeeding; benefit to the mother should outweigh risk to the infant.
Do not store above 30°C. Keep out of the reach of children.
.png&w=384&q=75)